Drug Offers Some Hope for a Deadly Lung Cancer
TUESDAY, April 4, 2017 (HealthDay News) -- The cancer drug Opdivo (nivolumab) may offer hope of a longer life for some patients with advanced lung cancer, a new small study finds.
Currently, only about 5 percent of patients with advanced non-small-cell lung cancer survive five years or more. But that rate rose to about 16 percent among a group taking Opdivo, researchers reported Monday.
"For the first time we are reporting long-term survival for patients with advanced lung cancer," said lead researcher Dr. Julie Brahmer.
Brahmer is an associate professor of oncology at the Johns Hopkins University Institute for Cancer Immunotherapy in Baltimore.
Opdivo is an immunotherapy drug, which means it enlists the patient's own immune system to fight diseases such as cancer.
"Immune therapy may play a role in almost any cancer. We are working to increase the response in lung cancer patients," Brahmer said.
Opdivo works by blocking the activity of a protein called PD-1. This allows the patient's immune system to kill cancer cells, according to the U.S. National Cancer Institute.
It's not yet possible to tell which patients might benefit from the drug. It may be that patients with high levels of PD-1 will benefit most, Brahmer said.
Other cancer specialists welcomed the report.
"This is incredible news that a single PD-1 inhibitor currently used as standard of care can cure 16 percent of patients with advanced lung cancer," said Dr. Yanis Boumber, an assistant professor of hematology and oncology at Fox Chase Cancer Center in Philadelphia.
"Of course, the bar will keep rising in advanced lung cancer, and combination immunotherapy treatments are expected to raise this number in the future," said Boumber, who wasn't involved in the study. "But for now, this is extremely exciting."
Opdivo is approved in the United States as a treatment for advanced non-small-cell lung cancer after other treatments fail, Brahmer said.
Immunotherapy treatments tend to be very costly, but the researchers behind the study could not offer a price tag. Opdivo is covered by insurance, the researchers said.
The new survival data come from long-term follow-up of the initial phase 1 clinical trial -- the first of three that preceded approval. In that trial, 129 patients with non-small-cell lung cancer that had spread elsewhere in the body were treated with one of three doses of the drug for two years.
For this report, patients were followed for a minimum of about 58 months. Sixteen patients survived for five years or longer, the researchers said.
However, four patients stopped treatment early because of side effects, Brahmer said.
Further research is needed to understand more about patients' responses, including who can discontinue treatment at two years and who will need more treatment, she said.
Most patients who have failed chemotherapy are candidates for this drug, Brahmer said. However, Opdivo might not be suitable for someone with an autoimmune disease, such as lupus, or for transplant recipients, she noted.
In addition to lung cancer, Opdivo is approved to treat melanoma, head and neck cancer, Hodgkin lymphoma, kidney cancer and bladder cancer, according to the U.S. National Cancer Institute.
Kim Norris is president of the Lung Cancer Foundation of America. "Immunotherapy in lung cancer is proving to be a game changer," she said.
"For years lung cancer had no treatment options, and people were told to go home and put their affairs in order," Norris said. "What this does is give lung cancer patients, especially those with advanced disease, a level of hope that we never have had before."
The new study results were presented Monday at the annual meeting of the American Association for Cancer Research in Washington, D.C. The study was funded by Bristol-Myers Squibb, the maker of Opdivo.
Research presented at meetings should be considered preliminary until published in a peer-reviewed medical journal.
For more on lung cancer, visit the American Cancer Society.
SOURCES: Julie Brahmer, M.D., associate professor, oncology, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore; Yanis Boumber, M.D., Ph.D., assistant professor, hematology/oncology, Fox Chase Cancer Center, Philadelphia; Kim Norris, president, Lung Cancer Foundation of America; April 3, 2017, presentation, American Association for Cancer Research, meeting, Washington, D.C.